JP4148662B2
(ja)
*
|
2000-08-10 |
2008-09-10 |
第一三共株式会社 |
ヌクレオシド及びオリゴヌクレオチド類縁体を含有する核酸試薬及び医薬
|
RU2233844C2
(ru)
*
|
1999-02-12 |
2004-08-10 |
Санкио Компани Лимитед |
Новые нуклеозидные и олигонуклеотидные аналоги
|
DE60109047T2
(de)
*
|
2000-09-07 |
2006-04-06 |
Avecia Biotechnology, Inc., Milford |
Synthone zur herstellung von oligonukleotiden
|
KR20020069627A
(ko)
*
|
2001-02-27 |
2002-09-05 |
동부한농화학 주식회사 |
육환의 아자슈거를 가진 뉴클레오타이드 유도체를 포함한포스포로티오에이트 올리고뉴클레오타이드 및 이들의에이즈 치료제로서의 새로운 용도
|
WO2003068795A1
(fr)
*
|
2002-02-13 |
2003-08-21 |
Takeshi Imanishi |
Analogues de nucleoside et derive d'oligonucleotide comprenant un analogue nucleotidique de ces composes
|
US20040219565A1
(en)
|
2002-10-21 |
2004-11-04 |
Sakari Kauppinen |
Oligonucleotides useful for detecting and analyzing nucleic acids of interest
|
US20050089889A1
(en)
|
2003-06-20 |
2005-04-28 |
Ramsing Niels B. |
Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same
|
US8415100B2
(en)
|
2003-08-14 |
2013-04-09 |
Case Western Reserve University |
Methods and compositions for detecting gastrointestinal and other cancers
|
CA2535910C
(en)
*
|
2003-08-14 |
2016-04-26 |
Case Western Reserve University |
Methods and compositions for detecting colon cancers
|
ATE404697T1
(de)
*
|
2003-11-07 |
2008-08-15 |
Daiichi Sankyo Co Ltd |
Verfahren zum nachweis von genetischem polymorphismus
|
US8192937B2
(en)
|
2004-04-07 |
2012-06-05 |
Exiqon A/S |
Methods for quantification of microRNAs and small interfering RNAs
|
WO2006069584A2
(en)
|
2004-12-29 |
2006-07-06 |
Exiqon A/S |
NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs
|
US20070065840A1
(en)
*
|
2005-03-23 |
2007-03-22 |
Irena Naguibneva |
Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
|
PL2314594T3
(pl)
|
2006-01-27 |
2014-12-31 |
Isis Pharmaceuticals Inc |
Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych
|
EP2505648A1
(en)
|
2006-05-05 |
2012-10-03 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of PTP1B
|
DK2363481T3
(en)
*
|
2006-05-05 |
2017-06-26 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating gene expression
|
US7666854B2
(en)
*
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
JP5441688B2
(ja)
*
|
2006-05-11 |
2014-03-12 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
5’修飾二環式核酸類似体
|
AU2007310989B2
(en)
|
2006-10-18 |
2014-05-29 |
Isis Pharmaceuticals, Inc. |
Antisense compounds
|
US8188255B2
(en)
|
2006-10-20 |
2012-05-29 |
Exiqon A/S |
Human microRNAs associated with cancer
|
WO2008046911A2
(en)
|
2006-10-20 |
2008-04-24 |
Exiqon A/S |
Novel human micrornas associated with cancer
|
JP2010510807A
(ja)
*
|
2006-11-27 |
2010-04-08 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
高コレステロール血症を治療するための方法
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
EP2113567B1
(en)
|
2006-12-21 |
2019-04-03 |
QIAGEN GmbH |
MicroRNA target site blocking oligos and uses thereof
|
US20090137504A1
(en)
*
|
2006-12-21 |
2009-05-28 |
Soren Morgenthaler Echwald |
Microrna target site blocking oligos and uses thereof
|
US8048998B2
(en)
|
2007-01-19 |
2011-11-01 |
Exiqon A/S |
Mediated cellular delivery of LNA oligonucleotides
|
EP2170917B1
(en)
|
2007-05-30 |
2012-06-27 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
ES2386492T3
(es)
|
2007-06-08 |
2012-08-21 |
Isis Pharmaceuticals, Inc. |
Análogos de ácidos nucleicos bicíclicos carbocíclicos
|
US8278283B2
(en)
*
|
2007-07-05 |
2012-10-02 |
Isis Pharmaceuticals, Inc. |
6-disubstituted or unsaturated bicyclic nucleic acid analogs
|
US8546556B2
(en)
*
|
2007-11-21 |
2013-10-01 |
Isis Pharmaceuticals, Inc |
Carbocyclic alpha-L-bicyclic nucleic acid analogs
|
EP2229583B1
(en)
|
2007-12-06 |
2019-04-10 |
Genalyte Inc. |
Label-free nucleic acid synthesis monitoring system and method
|
WO2009100320A2
(en)
*
|
2008-02-07 |
2009-08-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexitol nucleic acid analogs
|
DK2285819T3
(da)
*
|
2008-04-04 |
2013-12-02 |
Isis Pharmaceuticals Inc |
Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider
|
AU2009256243A1
(en)
|
2008-06-04 |
2009-12-10 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression through endogenous small RNA targeting of gene promoters
|
CA2732343C
(en)
|
2008-07-29 |
2017-05-09 |
The Board Of Regents Of The University Of Texas System |
Selective inhibition of polyglutamine protein expression
|
DK2356129T3
(da)
*
|
2008-09-24 |
2013-05-13 |
Isis Pharmaceuticals Inc |
Substituerede alpha-L-bicykliske nukleosider
|
WO2010062627A2
(en)
|
2008-10-27 |
2010-06-03 |
Genalyte Inc. |
Biosensors based on optical probing and sensing
|
WO2010124231A2
(en)
|
2009-04-24 |
2010-10-28 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
|
US20120108800A1
(en)
|
2009-06-23 |
2012-05-03 |
Shumpei Murata |
Method for synthesizing nucleic acid
|
EP2458005A1
(en)
|
2009-07-23 |
2012-05-30 |
Galaxy Pharma Inc. |
Fgf21 cis-element binding substance
|
EP2462153B1
(en)
|
2009-08-06 |
2015-07-29 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
US20110110860A1
(en)
|
2009-11-02 |
2011-05-12 |
The Board Of Regents Of The University Of Texas System |
Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
|
WO2011085102A1
(en)
|
2010-01-11 |
2011-07-14 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
US9574191B2
(en)
|
2010-02-03 |
2017-02-21 |
The Board Of Regents Of The University Of Texas System |
Selective inhibition of polyglutamine protein expression
|
WO2011115818A1
(en)
|
2010-03-17 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP3173419A1
(en)
|
2010-04-28 |
2017-05-31 |
Ionis Pharmaceuticals, Inc. |
Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
|
SG184938A1
(en)
|
2010-04-30 |
2012-11-29 |
Exiqon As |
In situ hybridization method and buffer
|
WO2011156278A1
(en)
|
2010-06-07 |
2011-12-15 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
CA3060724A1
(en)
|
2010-11-05 |
2012-05-10 |
Genalyte, Inc. |
Optical analyte detection systems and methods of use
|
EP3067421B1
(en)
|
2011-02-08 |
2018-10-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
EP2495336B8
(en)
|
2011-03-04 |
2014-07-23 |
Roche Diagnostics GmbH |
A new type of universal probes for the detection of genomic variants
|
EP4269584A3
(en)
|
2011-08-11 |
2024-03-27 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
US10557136B2
(en)
|
2011-12-12 |
2020-02-11 |
Oncolmmunin Inc. |
In vivo delivery of oligonucleotides
|
EP2825885B1
(en)
|
2012-03-12 |
2021-05-12 |
The Board of Trustees of the University of Illinois |
Optical analyte detection systems with magnetic enhancement
|
WO2013148283A1
(en)
|
2012-03-30 |
2013-10-03 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
|
US9221864B2
(en)
|
2012-04-09 |
2015-12-29 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2839006B1
(en)
|
2012-04-20 |
2018-01-03 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
US9993522B2
(en)
|
2012-09-18 |
2018-06-12 |
Uti Limited Partnership |
Treatment of pain by inhibition of USP5 de-ubiquitinase
|
KR101707437B1
(ko)
*
|
2012-09-21 |
2017-02-16 |
고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 |
구아니딘 가교를 갖는 인공 뉴클레오시드 및 올리고뉴클레오티드
|
ES2701235T3
(es)
|
2012-09-28 |
2019-02-21 |
Bna Inc |
Método de abrazadera de BNA
|
EP2906699A4
(en)
|
2012-10-11 |
2016-06-08 |
Ionis Pharmaceuticals Inc |
OLIGOMER COMPOUNDS WITH BICYCLIC NUCLEOSIDES AND USES THEREOF
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
US10723754B2
(en)
|
2012-10-22 |
2020-07-28 |
Idenix Pharmaceuticals Llc |
2′,4′-bridged nucleosides for HCV infection
|
EP2929050A1
(en)
|
2012-12-10 |
2015-10-14 |
AdvanDx, Inc. |
Use of probes for mass spectrometric identification of microorganisms or cells and associated conditions of interest
|
WO2014112463A1
(ja)
*
|
2013-01-15 |
2014-07-24 |
国立大学法人大阪大学 |
スルホンアミド構造を有するヌクレオシドおよびヌクレオチド
|
EP2961853B1
(en)
|
2013-02-28 |
2018-09-19 |
The Board of Regents of The University of Texas System |
Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
|
US10086093B2
(en)
|
2013-02-28 |
2018-10-02 |
The General Hospital Corporation |
miRNA profiling compositions and methods of use
|
US9273349B2
(en)
|
2013-03-14 |
2016-03-01 |
Affymetrix, Inc. |
Detection of nucleic acids
|
CN111254145A
(zh)
|
2013-03-14 |
2020-06-09 |
Ionis制药公司 |
用于调节tau表达的组合物和方法
|
WO2014179625A1
(en)
|
2013-05-01 |
2014-11-06 |
Isis Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION
|
TWI702046B
(zh)
|
2013-07-19 |
2020-08-21 |
美商Ionis製藥公司 |
用於調節τ蛋白表現之組合物
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
PL3126499T3
(pl)
|
2014-04-01 |
2020-11-30 |
Biogen Ma Inc. |
Kompozycje do modulowania ekspresji sod-1
|
WO2015168172A1
(en)
|
2014-04-28 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
AU2015252858C1
(en)
|
2014-05-01 |
2021-09-16 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating Complement Factor B expression
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
JP6867945B2
(ja)
|
2014-10-03 |
2021-05-12 |
コールド スプリング ハーバー ラボラトリー |
核内遺伝子出力の標的とされた増強
|
WO2016100716A1
(en)
|
2014-12-18 |
2016-06-23 |
Vasant Jadhav |
Reversirtm compounds
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
US10793855B2
(en)
|
2015-01-06 |
2020-10-06 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
US10407678B2
(en)
|
2015-04-16 |
2019-09-10 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
EP3919619A1
(en)
|
2015-07-17 |
2021-12-08 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
CN108603230A
(zh)
|
2015-10-09 |
2018-09-28 |
南安普敦大学 |
基因表达的调节与蛋白质表达失调的筛选
|
EP3389670A4
(en)
|
2015-12-04 |
2020-01-08 |
Ionis Pharmaceuticals, Inc. |
METHODS OF TREATING BREAST CANCER
|
WO2017106377A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
WO2017111137A1
(ja)
*
|
2015-12-22 |
2017-06-29 |
味の素株式会社 |
オリゴヌクレオチドの製造方法
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
AU2017234678A1
(en)
|
2016-03-16 |
2018-08-16 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating KEAP1
|
CA3023514A1
(en)
|
2016-06-17 |
2017-12-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
CN109952378A
(zh)
|
2016-09-14 |
2019-06-28 |
詹森生物制药有限公司 |
经修饰的寡核苷酸及使用方法
|
JOP20190065A1
(ar)
|
2016-09-29 |
2019-03-28 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن tau
|
EP3548620A4
(en)
|
2016-12-02 |
2020-07-22 |
Cold Spring Harbor Laboratory |
MODULATION OF THE EXPRESSION OF LNC05
|
WO2018165564A1
(en)
|
2017-03-09 |
2018-09-13 |
Ionis Pharmaceuticals, Inc. |
Morpholino modified oligomeric compounds
|
WO2019036613A1
(en)
|
2017-08-18 |
2019-02-21 |
Ionis Pharmaceuticals, Inc. |
MODULATION OF THE NOTCH SIGNALING PATHWAY FOR THE TREATMENT OF RESPIRATORY DISORDERS
|
CA3073515A1
(en)
|
2017-08-25 |
2019-02-28 |
Stoke Therapeutics, Inc. |
Antisense oligomers for treatment of conditions and diseases
|
US10517889B2
(en)
|
2017-09-08 |
2019-12-31 |
Ionis Pharmaceuticals, Inc. |
Modulators of SMAD7 expression
|
WO2019053661A2
(en)
|
2017-09-14 |
2019-03-21 |
Alios Biopharma, Inc. |
GALNAC DERIVATIVES
|
JP2021515784A
(ja)
|
2018-03-13 |
2021-06-24 |
ヤンセン ファーマシューティカ エヌ.ベー. |
修飾オリゴヌクレオチド及びタウオパチーにおける使用方法
|
CA3098623A1
(en)
|
2018-05-07 |
2019-11-14 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery
|
CA3114396A1
(en)
|
2018-09-28 |
2020-04-02 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
PE20211869A1
(es)
|
2018-11-15 |
2021-09-21 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresion de irf5
|
US20200222875A1
(en)
*
|
2018-12-26 |
2020-07-16 |
Twist Bioscience Corporation |
Highly accurate de novo polynucleotide synthesis
|
SG11202107399WA
(en)
|
2019-01-31 |
2021-08-30 |
Ionis Pharmaceuticals Inc |
Modulators of yap1 expression
|
US11279932B2
(en)
|
2019-02-27 |
2022-03-22 |
Ionis Pharmaceuticals, Inc. |
Modulators of MALAT1 expression
|
BR112021021686A2
(pt)
|
2019-05-03 |
2022-03-22 |
Dicerna Pharmaceuticals Inc |
Moléculas inibidoras de ácido nucleico de fita dupla com fitas senso curtas
|
EP3969052A1
(en)
|
2019-05-17 |
2022-03-23 |
Alnylam Pharmaceuticals Inc. |
Oral delivery of oligonucleotides
|
EP3956450A4
(en)
|
2019-07-26 |
2022-11-16 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR MODULATION OF GFAP
|
JP2022544587A
(ja)
|
2019-08-15 |
2022-10-19 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
結合修飾オリゴマー化合物及びその使用
|
EP4055165A1
(en)
|
2019-11-06 |
2022-09-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
CN114945669A
(zh)
|
2019-11-06 |
2022-08-26 |
阿尔尼拉姆医药品有限公司 |
肝外递送
|
MX2022012255A
(es)
|
2020-03-31 |
2023-01-11 |
Janssen Biopharma Inc |
Sintesis de oligonucleotidos y compuestos relacionados.
|
KR20230022409A
(ko)
|
2020-05-11 |
2023-02-15 |
스톡 테라퓨틱스, 인크. |
병태 및 질환의 치료를 위한 opa1 안티센스 올리고머
|
EP4271695A2
(en)
|
2020-12-31 |
2023-11-08 |
Alnylam Pharmaceuticals, Inc. |
2'-modified nucleoside based oligonucleotide prodrugs
|
CA3207125A1
(en)
|
2020-12-31 |
2022-07-07 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
AU2022249318A1
(en)
|
2021-03-31 |
2023-10-12 |
Entrada Therapeutics, Inc. |
Cyclic cell penetrating peptides
|
WO2022240721A1
(en)
|
2021-05-10 |
2022-11-17 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
|
CA3217463A1
(en)
|
2021-05-10 |
2022-11-17 |
Ziqing QIAN |
Compositions and methods for modulating mrna splicing
|
KR20240012425A
(ko)
|
2021-05-10 |
2024-01-29 |
엔트라다 테라퓨틱스, 인크. |
세포내 치료제를 위한 조성물 및 방법
|
EP4359006A1
(en)
|
2021-06-23 |
2024-05-01 |
Entrada Therapeutics, Inc. |
Antisense compounds and methods for targeting cug repeats
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
EP4373937A1
(en)
|
2021-07-21 |
2024-05-29 |
Alnylam Pharmaceuticals, Inc. |
Metabolic disorder-associated target gene irna compositions and methods of use thereof
|
CA3229661A1
(en)
|
2021-09-01 |
2023-03-09 |
Xiang Li |
Compounds and methods for skipping exon 44 in duchenne muscular dystrophy
|
IL311864A
(en)
|
2021-10-15 |
2024-06-01 |
Alnylam Pharmaceuticals Inc |
IRNA compositions for extrahepatic administration and methods of using them
|
WO2023220744A2
(en)
|
2022-05-13 |
2023-11-16 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded loop oligonucleotides
|
WO2024006999A2
(en)
|
2022-06-30 |
2024-01-04 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
WO2024040041A1
(en)
|
2022-08-15 |
2024-02-22 |
Dicerna Pharmaceuticals, Inc. |
Regulation of activity of rnai molecules
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
WO2024073732A1
(en)
|
2022-09-30 |
2024-04-04 |
Alnylam Pharmaceuticals, Inc. |
Modified double-stranded rna agents
|